OxFORD Asset Management LLP Has $500,000 Holdings in ABIOMED, Inc. (ABMD)
OxFORD Asset Management LLP lessened its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 45.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,002 shares of the medical equipment provider’s stock after selling 2,452 shares during the quarter. OxFORD Asset Management LLP’s holdings in ABIOMED were worth $500,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Seven Eight Capital LP bought a new stake in shares of ABIOMED in the 2nd quarter worth $100,000. Rehmann Capital Advisory Group bought a new stake in shares of ABIOMED in the 3rd quarter worth $202,000. Sigma Planning Corp acquired a new stake in shares of ABIOMED during the third quarter worth $206,000. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of ABIOMED during the third quarter worth $215,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ABIOMED by 15.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,511 shares of the medical equipment provider’s stock worth $217,000 after purchasing an additional 197 shares during the period. 90.45% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently issued reports on the company. Jefferies Group boosted their target price on ABIOMED from $208.00 to $220.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. BidaskClub lowered ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a research report on Tuesday, November 7th. SunTrust Banks reaffirmed a “buy” rating and set a $195.00 target price on shares of ABIOMED in a research report on Wednesday, November 1st. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research report on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. ABIOMED presently has a consensus rating of “Buy” and a consensus target price of $192.14.
In related news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the transaction, the vice president now directly owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares in the company, valued at $7,079,390.56. The disclosure for this sale can be found here. Insiders have sold 27,646 shares of company stock worth $4,836,333 over the last three months. 7.00% of the stock is owned by insiders.
Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at $190.42 on Thursday. The stock has a market capitalization of $8,380.00, a price-to-earnings ratio of 93.80, a PEG ratio of 2.55 and a beta of 0.15. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. ABIOMED, Inc. has a 52-week low of $103.53 and a 52-week high of $200.28.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.16. The firm had revenue of $132.80 million for the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. ABIOMED’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 earnings per share. research analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with Analyst Ratings Network's FREE daily email newsletter.